相关实验视频
Updated: Jul 5, 2025
06:41
Veno-Venous Extracorporeal Membrane Oxygenation in a Mouse
Published on: October 24, 2018
12.5K
多重血栓,包括心内血栓,伴随着在ECMO期间的HIT成功地用NOACs治疗:一个病例报告
Won-Sik Yun1, Sanghyo Kim1, Lae-Young Jung1,2,3
1Division of Cardiology, Hospital and Jeonbuk National University Medical School, Jeonbuk National University, Jeonju, Korea.
Perfusion
|January 19, 2024
概括
在体外膜氧化 (ECMO) 过程中,肝素诱导的血小板缺血 (HIT) 是罕见但严重的. 这一案例证明了使用新型口服抗凝剂 (NOACs) 成功治疗多重血栓形成的HIT.
科学领域:
- 心脏病学 心脏病学
- 血液学 血液学 血液学
- 临界护理医学 临界护理医学
背景情况:
- 未分离的氨酸是体外膜氧化 (ECMO) 过程中抗凝剂的标准.
- 氨酸使用带有氨酸诱导的血小板缺血 (HIT) 的风险,这是一个严重的并发症.
- HIT可以导致危及生命的血栓事件.
研究的目的:
- 在ECMO期间报告一个罕见的HIT病例与多重血栓形成.
- 突出新型口服抗凝剂 (NOACs) 在ECMO期间管理HIT的成功使用.
- 建议NOAC作为ECMO患者中HIT的潜在治疗选择.
主要方法:
- 一名50岁的男性患者患有心脏性休克,心肌梗塞后需要ECMO.
- 患者患有多重血栓塞并被诊断为HIT.
- 治疗涉及从肝素过渡到NOACs.
主要成果:
- 在ECMO期间,NOACs取得了成功的抗凝固作用.
- 患者没有经历与抗凝血疗法相关的重大并发症.
- 这代表了在ECMO的背景下首次报告NOAC用于HIT的案例.
结论:
- 在ECMO期间的HIT导致多重血栓形成,这是一个不常见但关键的临床场景.
- 新型口服抗凝剂 (NOACs) 提供了一个可行的替代方案,用于ECMO患者的抗凝.
- 及时识别和替代抗凝策略对于管理ECMO患者的HIT至关重要.
相关概念视频
01:30Anticoagulant Drugs: Low-Molecular-Weight Heparins
701
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
701
01:24Disorders of Hemostasis
918
Hemostasis, the process that stops bleeding after a blood vessel injury, is crucial for maintaining the integrity of the circulatory system. However, disorders of hemostasis can disrupt this delicate balance, leading to either excessive clotting or bleeding. These disorders can be broadly classified into thromboembolic disorders and bleeding disorders.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
918